Mushroom product manufacturer Nammex (North American Resihi Ltd) has filed a citizen petition with the FDA to clarify the labeling of fungal ingredients. Nammex says it has been advocating for many years for more transparency in the labeling of these products. The company advocates that fungal ingredient labeling practice should follow the lead of botanicals, in which labeling of the plant parts is required.
While an FDA regulation requires listing part of the plant from which a dietary ingredient originates, “the regulation is silent with respect to the requirement to list the ‘part’ e.g., ‘mushroom,’ ‘mycelium,’ [or] ‘spore’ from which a fungal ingredient is derived,” Nammex wrote to FDA.
“Nammex believes this lack of clarity in the regulation has created confusion in the marketplace and opened the door for the deceptive marketing of dietary supplements containing ingredients from fungi,” the citizen petition added. “Thus, FDA should amend the cited dietary supplement labeling regulations to expressly mandate that the part of the fungus from which a fungal ingredient is derived must be listed on dietary supplement labels, along with the common or usual name of the fungus from which the fungal part is derived, as is expressly required for herbs and botanicals.”
Source: naturalproductsinsider.com
